newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - NEKTAR THERAPEUTICS

  • Financial Performance:

    • No specific financial metrics (revenue, earnings, margins, cash flow, or debt) were disclosed in the provided transcript, as the discussion focused exclusively on clinical pipeline data and business strategy.
    • The company is currently in a pre-revenue biotech stage, having recently completed Phase II trials and initiating Phase III studies.
  • Guidance and Future Outlook:

    • Phase III Atopic Dermatitis (AD): Three pivotal studies (Zenith AD1, AD2, AD3) are underway, having kicked off in Summer 2026; top-line readouts are expected mid-2028.
    • Phase III Alopecia Areata (AA): A single registrational study (850 patients, age 12+) is set to commence in December 2026, with data expected in 2029; regulators have indicated this single study could support approval.
    • Next Data Catalyst: A detailed 52-week maintenance and 12-month off-drug durability data update for AD is scheduled for Q1 2027.
    • Long-term Goal: Establish RESPEG as a disease-modifying therapy capable of long-term efficacy post-treatment cessation.
  • Business Segments and Product Lines:

    • Core Asset: RESPEG (pegylated Aldoleukin), the most advanced regulatory T-cell (Treg) targeting agent in development.
    • Mechanism: Targets immune regulation to induce durable remission by normalizing immune pathways beyond the Th2 axis.
    • Indication Portfolio:
      • Atopic Dermatitis: Demonstrated rapid itch/skin clearance; 1/3 of patients achieved EASI-100 (complete clearance) after 52 weeks on a quarterly dosing regimen; efficacy maintained and improved during a 6-month off-drug period.
      • Alopecia Areata: Achieved hair regrowth rates comparable to JAK inhibitors at 1 year; notably, the majority of patients maintained or improved hair regrowth during a 6-month off-drug period, with SALT10 (90%+ regrowth) tripling over that time.
    • New Development: Phase III programs designed to test monotherapy in biologic/JAK-experienced patients (AD) and as an add-on to topical corticosteroids (AD) to support global labeling.
  • Market and Competitive Landscape:

    • Competitive Benchmarking: Directly compared against Dupixent (dupilumab) in AD and JAK inhibitors (e.g., Olumiant) in AA.
    • Differentiation:
      • Durability: Unique "off-drug" durability where efficacy persists or improves after treatment cessation, contrasting with JAK inhibitors where hair loss resumes upon stopping treatment.
      • Dosing: Potential for once-quarterly maintenance dosing, versus Dupixent's twice-monthly perpetual dosing.
      • Comorbidity: Demonstrated efficacy in treating co-morbid asthma and rhinosinusitis in AD patients, a capability currently limited mostly to Dupixent.
    • Market Strategy: Positioning to cover the full spectrum of patient populations (biologic-naive, experienced, and JAK-experienced) to secure a differentiated label.
  • Risks and Challenges:

    • Clinical Design Complexity: The off-drug durability study design (no sham injection, no rescue medication) presents analytical challenges regarding patient dropouts and maintenance definitions, though management is confident in the statistical power (125 patients in the maintenance cohort).
    • Regulatory Acceptance: Uncertainty regarding the acceptance of off-drug data as a primary efficacy metric compared to standard randomized withdrawal trials.
    • Competition: Intense competition in the atopic dermatitis and alopecia areata spaces with established biologics and JAK inhibitors.
    • Safety: Potential for toxicity issues in prior JAK inhibitor users, though management expects RESPEG to aid this specific cohort.
  • Management Commentary and Tone:

    • Tone: Highly confident and enthusiastic, citing the Nobel Prize-winning science of Tregs and early Phase I/II data as validation.
    • Strategic Focus: Emphasizes the novelty of the mechanism (Treg targeting) and the potential to "fix" underlying immune dysfunction rather than just symptom suppression.
    • Advisor Alignment: Management reports strong feedback from physician advisors regarding the potential for a disruptive new MOA.
  • Analyst Questions and Answers:

    • Q: How does the Phase II AD off-drug design compare to Dupixent's "Solo Continue" trial?
      • A: The design differs by lacking a sham injection and extending observation to 12 months (vs. Dupixent's 9 months). Management aims to match or exceed Dupixent's ~50% maintenance of EASI-75 at the 9-month mark, using methodologies similar to literature reviews of other trials to handle dropouts.
    • Q: What is the impact of adding topical corticosteroids (TCS) to the AD Phase III design?
      • A: The design (Zenith AD2) tests RESPEG + TCS vs. TCS + placebo to meet global regulatory expectations for combination therapy. Preclinical data shows synergistic effects, allowing for reduced steroid dosing while maintaining high statistical power (510 patients per study).
    • Q: How will RESPEG fit into the AD market with evolving Th2 inhibitors?
      • A: Early proteomic data shows RESPEG normalizes Th1, Th2, and Th17 pathways within two weeks. The unique selling point is the ability to treat comorbidities (asthma, rhinosinusitis) and the potential for long-term remission after stopping therapy.
    • Q: Why combine JAK-experienced and naive patients in the AA Phase III study?
      • A: Regulators require a representative real-world population. While most AA patients are JAK-naive, including JAK-experienced patients allows RESPEG to demonstrate efficacy in those who failed prior therapies due to toxicity.
  • Other Key Points:

    • Scientific Mechanism: ResPeg uniquely normalizes systemic and local immunological pathways (including fibrotic and cardiac health signatures) as early as week two, suggesting a disease-modifying effect.
    • Data Presentation: Rhinosinusitis and allergy comorbidity data for AD is scheduled for presentation in early 2027.
    • Conference Context: This update was provided at the 2026 Jeffries Global Healthcare Conference in London by Nectar Therapeutics (Head of R&D: Jay-Z, noted as "Jay" in transcript).
Company
NEKTAR THERAPEUTICS
Keywords
NEKTAR THERAPEUTICS